McDonald Alice, Karnik Rahul, Campbell Veronica, Davis Jeff, Chavoshi Sara, Slavin Anthony, Sharma Kirti, Gollob Jared, Alavi Afsaneh
Kymera Therapeutics, Watertown, Massachusetts, USA.
Kymera Therapeutics, Watertown, Massachusetts, USA.
J Invest Dermatol. 2025 Feb;145(2):323-333.e10. doi: 10.1016/j.jid.2024.04.035. Epub 2024 Jul 29.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease manifesting as painful dermal nodules, abscesses, and tunnels. Activation of the IL-1R/toll-like receptor pathway is strongly implicated in the pathogenesis of HS; thus, the role of a key signaling node, IRAK4, was investigated in a noninterventional study (NCT04440410) that enrolled 30 patients with HS. IRAK4 expression was evaluated in blood and lesional, perilesional, and nonlesional skin biopsies. PBMCs expressed IRAK4, with significantly higher levels in monocytes (P ≤ .0001). Ex vivo treatment of PBMCs with KT-474, a targeted degrader of IRAK4, robustly decreased IRAK4 in all immune cell types from healthy volunteers and patients with HS. Ex vivo treatment of toll-like receptor-stimulated healthy donor monocytes with KT-474 decreased IRAK4 protein levels and inhibited inflammatory cytokine production. In HS skin samples, IRAK4 protein levels were significantly higher in lesional than in nonlesional tissue (P ≤ .0001), and IRAK4-positive immune infiltrate increased with greater disease severity. Multiple inflammatory mediators were upregulated in HS lesional skin, correlating with IRAK4 overexpression. These data confirm the significance of the IL-1R/toll-like receptor pathway in the pathogenesis of HS and provide support for ongoing clinical studies evaluating KT-474 in the treatment of HS.
化脓性汗腺炎(HS)是一种慢性炎症性疾病,表现为疼痛性皮肤结节、脓肿和窦道。IL-1R/ toll样受体途径的激活在HS的发病机制中起重要作用;因此,在一项纳入30例HS患者的非干预性研究(NCT04440410)中,对关键信号节点IRAK4的作用进行了研究。在血液以及病变、病变周围和非病变皮肤活检组织中评估IRAK4的表达。外周血单个核细胞(PBMC)表达IRAK4,单核细胞中的水平显著更高(P≤0.0001)。用IRAK4靶向降解剂KT-474对健康志愿者和HS患者的PBMC进行体外处理,可显著降低所有免疫细胞类型中的IRAK4水平。用KT-474对toll样受体刺激的健康供体单核细胞进行体外处理,可降低IRAK4蛋白水平并抑制炎性细胞因子的产生。在HS皮肤样本中,病变组织中的IRAK4蛋白水平显著高于非病变组织(P≤0.0001),并且IRAK4阳性免疫浸润随着疾病严重程度的增加而增加。HS病变皮肤中有多种炎性介质上调,与IRAK4的过表达相关。这些数据证实了IL-1R/ toll样受体途径在HS发病机制中的重要性,并为正在进行的评估KT-474治疗HS的临床研究提供了支持。